Molecular cloning and expression of novel alternatively spliced cytochrome P450 2E1 mRNAs in humans

Molecular and Cellular Biochemistry

Volumn 280, Issue 1-2, 2005, Pages 201-207

  Bauer, Mario ^a   Herbarth, Olf ^a   Aust, Gabi ^b   Graebsch, Carolin ^a  

^a HELMHOLTZ CENTRE FOR ENVIRONMENTAL RESEARCH UFZ   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Alternative splicing variant; Blood leukocyte; CYP2E1; Hepatocyte cell line; Human lung carcinoma cell line; Lung carcinoma

Indexed keywords

CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; MESSENGER RNA; XENOBIOTIC AGENT;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CONTROLLED STUDY; ENZYME LOCALIZATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LIVER CELL; LUNG CARCINOMA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RNA TRANSCRIPTION;

ALLELES; ALTERNATIVE SPLICING; CELL LINE, TUMOR; CLONING, MOLECULAR; CYTOCHROME P-450 CYP2E1; ETHANOL; EXONS; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; INTERLEUKIN-4; LEUKOCYTES; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 29244473583     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-005-0169-x     Document Type: Article

References (29)

1. Lieber CS: CytoIhrome P-4502E1: its physiological and pathological role. Physiol Rev 77: 517-544, 1997 9114822
2. Coon MJ, Koop DR: Alcohol-inducible cytochrome P-450 (P-450ALC). Arch Toxicol 60: 16-21, 1987 10.1007/BF00296940
3. Yang CS, Yoo JSR, Ishizaki H, Hong J: Cytochrome P450IIE1: role in nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 22: 147-159, 1990 2272285
4. Carriere V, Berthou F, Baird S, Belloc C, Beaune P, de Waziers I: Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype. Pharmacogenetics 6: 203-211, 1996 8807659
5. Cederbaum Al, Wu D, Mari M, Bai J: CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic Biol Med 31: 1539-1543, 2001 11744327
6. Tan W, Song N, Wang GQ, Liu Q, Tang HJ, Kadlubar FF, Lin DX: Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferase M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol Biomarker Prev 9: 551-556, 2000 1:CAS:528:DC%2BD3cXksVGjt7c%3D
7. Dupont I, Lucas D, Clot P, Menez C, Albano E: Cytochrome P4502E1 inducibility and hydroxyethyl radical formation among alcoholics. J Hepatol 28: 564-571, 1998 10.1016/S0168-8278(98)80279-1
8. O'Shea D, Davis SN, Kim RB, Wilkinson GR: Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin Pharmacol Ther 56: 359-367, 1994 7955797
9. Han XM, Zhou HH: Polymorphism of CYP450 and cancer susceptibility. Acta Pharmacol Sin 21: 673-679, 2000 11501173
10. Snawder JE, Lipscomb JC: Interindividual variance of cytochrome P450 forms in human hepatic microsomes: Correlation of individual forms with xenobiotic metabolism and implications in risk assessment. Regul Toxicol Pharmacol 32: 200-209, 2000 10.1006/rtph.2000.1424
11. Stephens EA, Taylor JA, Kaplan N, Yang CH, Hsieh LL, Lucier GW, Bell DA: Ethnic variation in the CYP2E1 gene polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Pharmacogenetics 4: 185-192, 1994 7987402
12. Persson I, Johansson I, Bergling H, Dahl ML, Seidegard J, Rylander R, Rannug A, Hogberg J, Sundberg MI: Genetic polymorphism of cytochrome P4502E1 in a Swedish population: Relationship to incidence of lung cancer. FEBS Lett 319: 207-211, 1993 10.1016/0014-5793(93)80547-8
13. Hildesheim A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, Reed CD, Chen IH, Caporaso NE, Hsu MM, Chen JY, Idle JR, Hoover RN, Yang CS, Chabra SK: CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 89: 1207-1212, 1997 9274915
14. Itoga S, Nomura F, Makino Y, Tomonaga T, Shimada H, Ochiai T, Iizasa T, Baba M, Fujisawa T, Harada S: Tandem repeat polymorphism of the CYP2E1 gene: An association study with esophageal cancer and lung cancer. Alcohol Clin Exp Res 26: 15S-19S, 2002 12198369
15. LeMarchand L, Donlon T, Seifried A, Wilkens LR: Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarker Prev 11: 1019-1024, 2002
16. Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzales FJ: Human ethanol-inducible P450IIE1: Complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27: 9006-9013, 1988 10.1021/bi00425a019
17. Gonzales FJ, Ueno T, Umeno M, Song BJ, Veech RL, Gelboin HV: Microsomal ethanol oxidazing system: Transcriptional and post-transcriptional regulation of cytochrome P450 CYP2E1. Alcohol Alcohol Suppl 1: 97-101, 1991
18. Abdel-Razzak Z, Garlatti M, Aggerbeck M, Barouki R: Determination of interleukin-4-responsive region in the human cytochrome P450 2E1 gene promoter. Biochem Pharmacol 68: 1371-1381, 2004 15345327
19. Lagadic-Gossmann D, Lerche C, Rissel M, Joannard F, Galisteo M, Guillouzo A, Corcos L: The induction of the human hepatic CYP2E1 gene by interleukin 4 is transcriptional and regulated by protein kinase C. Cell Biol Toxicol 16: 221-233, 2000 10.1023/A:1007625925095
20. Gonzalez FJ, Ueno T, Umeno M, Song BJ, Veech RL, Gelboin HV: Microsomal ethanol oxidizing system: Transcriptional and posttranscriptional regulation of cytochrome P450 CYP2E1. Alcohol Alcohol Suppl 1: 97-101, 1991 1845601
21. Song BJ, Matsunaga T, Hardwick JP, Park SS, Veech RL, Yang CS, Gelboin HV Gonzalez FJ: Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol Endocrinol 1: 542-547, 1987 3153476
22. Peng HM, Coon MJ: Regulation of rabbit cytochrome P450 2E1 expression in HepG2 cells by insulin and thyroid hormone. Mol Pharmacol 54: 740-747, 1998 9765518
23. Abdel Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A: Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44: 707-715, 1993 8232220
24. Choi JY, Lee KM, Cho SH, Kim SW, Choi HY, Lee SY, Im HJ, Yoon KJ, Choi H, Choi I, Hirvonen A, Hayes RB, Kang D: CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 13: 349-355, 2003 12777965
25. Piao YF, Li JT, Shi Y: Relationship between genetic polymorphism of cytochrome P450IIE1 and fatty liver. World J Gastroenterol 9: 2612-2615, 2003 14606109
26. Howard LA, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF: CYP2E1z.ast:1D regulatory polymorphism: Association with alcohol and nicotine dependence. Pharmacogenetics 13: 321-328, 2003 10.1097/ 00008571-200306000-00003
27. Kongruttanachok N, Sukdikul S, Setavarin S, Kerekhjanarong V, Supiyaphun P, Voravud N, Poovorawan Y, Mutirangura A: Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: A correlative study. BMC Cancer 1: 4, 2001 10.1186/1471-2407-1-4
28. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ: The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934 - A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 47: 99'3p4-1001, 1990 1978565
29. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki T, Kawamura J, Yatani R, Shiraishi T: Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165(2): 171-177, 2001 10.1016/ S0304-3835(01)00398-6